Sunshine Biopharma, Inc. () Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Cyclerion Therapeutics, Inc.

Sunshine Biopharma, Inc.

Blue Water Biotech, Inc.

Neurosense Therapeutics Ltd.

Talphera, Inc.

Theriva Biologics, Inc.

Shuttle Pharmaceuticals Holdings, Inc.

Trevena, Inc.

Virpax Pharmaceuticals, Inc.

Comera Life Sciences Holdings, Inc.

Timber Pharmaceuticals, Inc.

Why is Sunshine Biopharma, Inc. ?

Poor Management Efficiency with a low ROE of 0%

The company has reported losses. Due to this company has reported negative ROE
OPERATING CASH FLOW(Y) Highest at USD -7.75 MM
NET PROFIT(HY) Higher at USD -1.89 MM
RAW MATERIAL COST(Y) Fallen by -45.5% (YoY)

Risky - Negative EBITDA

The stock is trading risky as compared to its average historical valuations
Over the past year, while the stock has generated a return of -43.03%, its profits have fallen by -23%

Increasing Participation by Institutional Investors

Institutional investors have increased their stake by 1.81% over the previous quarter and collectively hold 5.32% of the company
These investors have better capability and resources to analyse fundamentals of companies than most retail investors

Below par performance in long term as well as near term

Along with generating -43.03% returns in the last 1 year, the stock has also underperformed S&P 500 in the last 3 years, 1 year and 3 months

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Sunshine Biopharma, Inc. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Sunshine Biopharma, Inc. for you?

High Risk, Low Return

Absolute

Risk Adjusted

Volatility

Sunshine Biopharma, Inc.

-48.39%

-1.10

73.98%

S&P 500

13.22%

0.61

20.17%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

106.23%

EBIT Growth (5y)

-230.67%

EBIT to Interest (avg)

-4.64

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.35

Sales to Capital Employed (avg)

1.13

Tax Ratio

5.58%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

5.32%

ROCE (avg)

ROE (avg)

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

0.30

EV to EBIT

0.18

EV to EBITDA

0.19

EV to Capital Employed

-0.07

EV to Sales

-0.03

PEG Ratio

Dividend Yield

ROCE (Latest)

Negative Capital Employed

ROE (Latest)

-22.16%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

RSI

No Signal

Bullish

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Bearish

Dow Theory

No Trend

Mildly Bearish

OBV

No Trend

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

9What is working for the Company

OPERATING CASH FLOW(Y)

Highest at USD -7.75 MM

NET PROFIT(HY)

Higher at USD -1.89 MM

RAW MATERIAL COST(Y)

Fallen by -45.5% (YoY

OPERATING PROFIT(Q)

Highest at USD -0.92 MM

OPERATING PROFIT MARGIN(Q)

Highest at -9.78 %

EPS(Q)

Highest at USD -0.39

-10What is not working for the Company

DEBT-EQUITY RATIO (HY)

Highest at -36.51 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 2.28 times

NET PROFIT(Q)

At USD -0.71 MM has Fallen at -43.44%

DEBTORS TURNOVER RATIO(HY)

Lowest at 9.61 times

Here's what is working for Sunshine Biopharma, Inc.

Operating Cash Flow

Highest at USD -7.75 MM

in the last three years

MOJO Watch

The company has generated higher cash revenues from business operations

Operating Cash Flows (USD MM)

Operating Profit

Highest at USD -0.92 MM

in the last five periods

MOJO Watch

Near term Operating Profit trend is positive

Operating Profit (USD MM)

Operating Profit Margin

Highest at -9.78 %

in the last five periods

MOJO Watch

Company's profit margin has improved

Operating Profit to Sales

EPS

Highest at USD -0.39

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (USD)

Raw Material Cost

Fallen by -45.5% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Sunshine Biopharma, Inc.

Net Profit

At USD -0.71 MM has Fallen at -43.44%

Year on Year (YoY)

MOJO Watch

Near term Net Profit trend is very negative

Net Profit (USD MM)

Debt-Equity Ratio

Highest at -36.51 % and Grown

In each half year in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Inventory Turnover Ratio

Lowest at 2.28 times and Fallen

In each half year in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio

Lowest at 9.61 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling Debtors has slowed

Debtors Turnover Ratio